In memoriam László Endrényi 😥 [Off Topic]

posted by Helmut Homepage – Vienna, Austria, 2020-12-17 21:44 (1281 d 21:14 ago) – Posting: # 22148
Views: 3,339

Dear all,

[image]on December 14th, László Endrényi, Professor Emeritus at Department of Pharmacology and Toxicology at the University of Toronto, passed away.

His book “Kinetic Data Analysis” 1 was among the first ones introducing me to the concepts of PK. I first met him in 1991 and was immediately impressed by his sharp mind and great sense of humor. Besides his influential work on various PK metrics 2 together with his – then – postdoc László Tóthfalusi he set the basics of reference-scaling in bioequivalence. Whilst he advised the Canadian agency for many years, like Don Quixote he fenced against the windmills of the FDA. I’m not sure whether Detlew Labes called the FDA’s RSABE a “hocus pocus” but with a smirk László adopted the term and used it ever since in private conversations and at conferences. Donald Schuir­mann was not amused.
I remember traveling together through Transylvania in 2013. Not vampires, but many hours of good discussion, full of laughter, and enduring terrible wine.
He gave me a hard time reviewing a couple of his manuscripts and I’m grateful for his critical but always helpful comments on ours. Without his enthusiasm (“I’m excited, you have to publish!”) they would still reside on the bottom of our todo-list.


R.I.P., my old friend!

Professor Laszlo Endrenyi (1933 – 2020)

  1. Endrényi L (editor). Kinetic Data Analysis. Design and Analysis of Enzyme and Pharmacokinetic Experiments. New York: Plenum Press; 1981.
  2. I was amazed when he introduced “POT”. No, you don’t smoke it – it’s the “Peak Occupancy Time”.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
23,059 posts in 4,841 threads, 1,664 registered users;
39 visitors (0 registered, 39 guests [including 7 identified bots]).
Forum time: 19:59 CEST (Europe/Vienna)

[…] an inappropriate study design is incapable of answering
a research question, no matter how careful the subsequent
methodology, conduct, analysis, and interpretation:
Flawless execution of a flawed design achieves nothing worthwhile.    J. Rick Turner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz